Medical Device Information
BGI PathoGenesis Pharmaceutical Technology Co., Ltd.

BGI PathoGenesis Pharmaceutical Technology Co., Ltd.

admin22025-09-05 12:52:21

About BGI PathoGenesis Pharmaceutical Technology Co., Ltd.

BGI PathoGenesis Pharmaceutical Technology Co., Ltd. (Shenzhen Huada Yuan Medical Technology Co., Ltd.) was founded on August 29, 2019, and is headquartered in Shenzhen, china. It is a wholly owned subsidiary of BGI Genomics Co., Ltd., a global leader in genomics. The company focuses on large-scale sequencing, gene testing technology, and big data platforms to provide genomic diagnostics and research services for healthcare, agriculture, and resource conservation. Its business scope covers R&D, production, and sales of medical devices, pharmaceuticals, and biotechnology products, as well as biotech consulting and technical services.

Core Business & Key Products

The company specializes in genomic research and diagnostics, with key products including:

  • Nucleic Acid Detection Kit for Bloodstream Infection Pathogens (Combinatorial Probe-Anchor Synthesis Technology): Enables qualitative detection of pathogen-free DNA in plasma samples; EU CE-certified in 2020.

  • SARS-CoV-2 Virus Antigen Detection Kit (Colloidal Gold Method): In vitro detection of COVID-19 antigens during acute infection; EU CE-certified in 2021.

  • Real-time Fluorescent RT-PCR Kit: Detects SARS-CoV-2, Influenza A, and Influenza B nucleic acids in throat swabs; EU CE-certified in 2021.

  • Multiplex Real-time Fluorescent RT-PCR Kit: Multi-pathogen detection kit; EU CE-certified in 2021.

Market Position & Strengths

As a subsidiary of BGI Genomics, BGI PathoGenesis benefits from world-class genomic expertise and resources. It has established a strong reputation in molecular diagnostics, with CE-certified kits addressing infectious disease detection. Its integration of advanced sequencing, bioinformatics, and data-driven platforms positions it as a key contributor to healthcare, agricultural innovation, and environmental conservation, reinforcing BGI’s leadership in global genomics applications.

Contact Information

Address: No. 59 Haiyun Center, Linhai Avenue, Nanshan Street, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen, China

Keywords: BGI PathoGenesis Pharmaceutical Technology Co., Ltd., BGI Genomics, genomic research, nucleic acid detection kit, SARS-CoV-2 antigen kit, RT-PCR

文章下方广告位

猜你喜欢

网友评论